EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing the management of prosthetic joint infections: a review of randomized controlled trials and emerging evidence

Burcu Isler iD, Zhenya Welyczko, Nicholas Jorgensen, Joshua Davis iD, David L Paterson

Antimicrobial Agents and Chemotherapy · 2025-10 · 69 (10)

DOI: 10.1128/aac.00338-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025-10. Verfasst von Burcu Isler und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Queensland Centre for Clinical Research, Brisbane, Australia. Hauptthemen laut MEDLINE: Prosthesis-Related Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prosthetic joint infections (PJI) remain among the most devastating complications in orthopedic surgery, with increasing incidence paralleling the growth in arthroplasty procedures worldwide. While treatment protocols are well-established, evidence supporting current approaches is lacking, and outcomes remain suboptimal, highlighting the need for improved therapeutic strategies. The objective of this study is to review ongoing and recently completed randomized controlled trials (RCTs) investigating novel approaches to PJI prevention and treatment. We searched PubMed and ClinicalTrials.gov databases for RCTs that focused on PJI management, and that are ongoing or completed within the 6 months preceding February 28, 2025. We included investigator-initiated trials, studies of novel therapeutic agents, and studies on infection prevention strategies. We extracted and reviewed data regarding trial design, interventions, and outcomes. We identified significant advances in three key areas: (i) investigator-initiated trials exploring optimization of current surgical and antimicrobial treatment strategies, including the ROADMAP adaptive platform trial (ii); novel therapeutic agents, including engineered antibacterial peptides, monoclonal antibodies, and new-generation antibiotics specifically targeting biofilm-associated infections; and (iii) prevention strategies, particularly focusing on perioperative antibiotic protocols. Recent trials demonstrate promising approaches to reducing antibiotic exposure while maintaining efficacy, novel mechanisms for biofilm disruption, and strategies for optimizing perioperative prophylaxis. Investigator-initiated trials like ROADMAP and SOLARIO are challenging traditional paradigms, particularly in antibiotic duration, while novel therapeutics targeting biofilm through various mechanisms show promise in early-phase trials. Future research should prioritize cost-effectiveness analyses, targeted studies for specific patient subgroups, and evaluation of combination therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prosthesis-Related InfectionsAnti-Bacterial AgentsHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

antibioticsclinical trialsprosthetic joint infectionsurgical management

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • University of Queensland Centre for Clinical Research, Brisbane, Australia.
  • Department of Infectious Diseases, Gold Coast University Hospital, Gold Coast, Australia.
  • Department of Orthopaedic Surgery, Princess Alexandra Hospital, Brisbane, Australia.
  • Infection Research Program, Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, Australia.
  • ADVANCE-ID, Saw Swee Hock School of Public Health and Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Burcu Isler, Joshua Davis

Zitieren

APA

Isler, B., Welyczko, Z., Jorgensen, N., Davis, J., & Paterson, D. L. (2025). Advancing the management of prosthetic joint infections: a review of randomized controlled trials and emerging evidence. Antimicrobial Agents and Chemotherapy, 69(10). https://doi.org/10.1128/aac.00338-25

Vancouver

Isler B, Welyczko Z, Jorgensen N, Davis J, Paterson DL. Advancing the management of prosthetic joint infections: a review of randomized controlled trials and emerging evidence. Antimicrobial Agents and Chemotherapy. 2025;69(10). doi:10.1128/aac.00338-25

BibTeX
@article{Isler2025,
  author = {Isler, Burcu and Welyczko, Zhenya and Jorgensen, Nicholas and Davis, Joshua and Paterson, David L},
  title = {Advancing the management of prosthetic joint infections: a review of randomized controlled trials and emerging evidence},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {10},
  doi = {10.1128/aac.00338-25}
}
Kostenlos starten →